Potential Cost-Effectiveness of RSV Vaccination of Infants and Pregnant Women in Turkey: An Illustration Based on Bursa Data

被引:20
作者
Pouwels, Koen B. [1 ,2 ]
Bozdemir, Sefika E. [3 ]
Yegenoglu, Selen [4 ]
Celebi, Solmaz [3 ]
McIntosh, E. David [5 ]
Unal, Serhat [6 ]
Postma, Maarten J. [1 ,7 ,8 ]
Hacimustafaoglu, Mustafa [3 ]
机构
[1] Univ Groningen, Dept Pharm, Unit PharmacoEpidemiol & PharmacoEcon, Groningen, Netherlands
[2] Publ Hlth England, Modelling & Econ Unit, Ctr Infect Dis Surveillance & Control, London, England
[3] Uludag Univ, Fac Med, Div Pediat Infect Dis, Bursa, Turkey
[4] Hacettepe Univ, Dept Pharm Management, Fac Pharm, Ankara, Turkey
[5] Imperial Coll London, Dept Med, London, England
[6] Hacettepe Univ, Dept Infect Dis & Clin Microbiol, Fac Med, Ankara, Turkey
[7] Univ Groningen, Univ Med Ctr Groningen, Inst Sci Hlth Aging & HealthcaRE SHARE, Groningen, Netherlands
[8] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, Groningen, Netherlands
关键词
RESPIRATORY-SYNCYTIAL-VIRUS; UNITED-STATES; HIGH-RISK; INFECTION; CHILDREN; INFLUENZA; MORTALITY; HOSPITALIZATION; PROPHYLAXIS; FREQUENCY;
D O I
10.1371/journal.pone.0163567
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background Worldwide, respiratory syncytial virus (RSV) is considered to be the most important viral cause of respiratory morbidity and mortality among infants and young children. Although no active vaccine is available on the market yet, there are several active vaccine development programs in various stages. To assess whether one of these vaccines might be a future asset for national immunization programs, modeling the costs and benefits of various vaccination strategies is needed. Objectives To evaluate the potential cost-effectiveness of RSV vaccination of infants and/or pregnant women in Turkey. Methods A multi-cohort static Markov model with cycles of one month was used to compare the cost-effectiveness of vaccinated cohorts versus non-vaccinated cohorts. The 2014 Turkish birth cohort was divided by twelve to construct twelve monthly birth cohorts of equal size (111,459 new-borns). Model input was based on clinical data from a multicenter prospective study from Bursa, Turkey, combined with figures from the (inter) national literature and publicly available data from the Turkish Statistical Institute (TUIK). Incremental cost-effectiveness ratios (ICERs) were expressed in Turkish Lira (TL) per quality-adjusted life year (QALY) gained. Results Vaccinating infants at 2 and 4 months of age would prevent 145,802 GP visits, 8,201 hospitalizations and 48 deaths during the first year of life, corresponding to a total gain of 1650 QALYs. The discounted ICER was estimated at 51,969 TL (26,220 US $ in 2013) per QALY gained. Vaccinating both pregnant women and infants would prevent more cases, but was less attractive from a pure economic point of view with a discounted ICER of 61,653 TL (31,106 US $ in 2013) per QALY. Vaccinating only during pregnancy would result in fewer cases prevented than infant vaccination and a less favorable ICER. Conclusion RSV vaccination of infants and/or pregnant women has the potential to be cost-effective in Turkey. Although using relatively conservative assumptions, all evaluated strategies remained slightly below the threshold of 3 times the GDP per capita.
引用
收藏
页数:15
相关论文
共 49 条
[1]   Mathematical modelling of respiratory syncytial virus (RSV): vaccination strategies and budget applications [J].
Acedo, L. ;
Diez-Domingo, J. ;
Morano, J. -A. ;
Villanueva, R. -J. .
EPIDEMIOLOGY AND INFECTION, 2010, 138 (06) :853-860
[2]   Brief History and Characterization of Enhanced Respiratory Syncytial Virus Disease [J].
Acosta, Patricio L. ;
Caballero, Mauricio T. ;
Polack, Fernando P. .
CLINICAL AND VACCINE IMMUNOLOGY, 2016, 23 (03) :189-195
[3]   Influenza A and respiratory syncytial virus hospital burden in young children in East London [J].
Ajayi-Obe, E. K. ;
Coen, P. G. ;
Handa, R. ;
Hawrami, K. ;
Aitken, C. ;
McIntosh, E. D. G. ;
Booy, R. .
EPIDEMIOLOGY AND INFECTION, 2008, 136 (08) :1046-1058
[4]   Strategic priorities for respiratory syncytial virus (RSV) vaccine development [J].
Anderson, L. J. ;
Dormitzer, P. R. ;
Nokes, D. J. ;
Rappuoli, R. ;
Roca, A. ;
Graham, B. S. .
VACCINE, 2013, 31 :B209-B215
[5]  
[Anonymous], 2014, Antimicrobial Resistance: Tackling a crisis forthe health and wealth of nations
[6]  
[Anonymous], 1999, PEDIATR INFECT DIS J, V18, P173
[7]   Excess drug prescriptions during influenza and RSV seasons in the Netherlands: Potential implications for extended influenza vaccination [J].
Assink, M. D. M. ;
Kiewiet, J. P. ;
Rozenbaum, M. H. ;
Van den Berg, P. B. ;
Hak, E. ;
Buskens, E. J. ;
Wilschut, J. C. ;
Kroes, A. C. M. ;
Postma, M. J. .
VACCINE, 2009, 27 (07) :1119-1126
[8]   Assessing Optimal Target Populations for Influenza Vaccination Programmes: An Evidence Synthesis and Modelling Study [J].
Baguelin, Marc ;
Flasche, Stefan ;
Camacho, Anton ;
Demiris, Nikolaos ;
Miller, Elizabeth ;
Edmunds, W. John .
PLOS MEDICINE, 2013, 10 (10)
[9]   Estimating and comparing the clinical and economic impact of paediatric rotavirus vaccination in Turkey using a simple versus an advanced model [J].
Bakir, Mustafa ;
Standaert, Baudouin ;
Turel, Ozden ;
Bilge, Zeynep Ece ;
Postma, Maarten .
VACCINE, 2013, 31 (06) :979-986
[10]   Cost-effectiveness of new pneumococcal conjugate vaccines in Turkey: a decision analytical model [J].
Bakir, Mustafa ;
Turel, Ozden ;
Topachevskyi, Oleksandr .
BMC HEALTH SERVICES RESEARCH, 2012, 12